Clinical Trial Search

Primary: Follow-up Duration — 1.07 years

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Progression-free Survival (PFS) - All Participants — 7.4 months

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Disease-free Survival — 192; 197 Participants — p=0.737

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649

Primary: Overall Response Rate — 27 percentage of patients

Primary: Progression Free Survival With Sunitinib as First Line of Therapy — 18.4 months

Primary: Percentage Change From Baseline in Tumour Size at 12 Weeks — -19.47; 19.65 Percentage change from baseline

Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants

Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081

Primary: Progression Free Survival (PFS) — 11 months

Primary: Progression-free Survival — 12 Weeks

Primary: The Sensitivity of Detecting RCC Recurrence (Using Contrast-enhanced MRI as a Reference Standard) on a Single Contrast-enhanced Ultrasound Exam. — 100 percent of patients

Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants

Primary: Disease-free Survival (DFS)- Assessed by Blinded Independent Central Review — 6.8; 5.6 Number of years — p=0.030

Primary: Metabolic Response — 5 participants

Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants

Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants

Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants

Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants

Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants

Primary: Progression Free Survival (PFS) — 5.5 Months

Primary: Response Rate — 0 percentage of participants

Primary: Percentage of Progression-free Patients by Month 6 — 8.3; 46.2 Percentage of participants

Primary: Time to Diagnose Metastatic Renal Cell Carcinoma — 3.79; 0.21 Years — p=<0.001

Primary: Progression Free Survival (PFS) — NA months

Primary: Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population — 542; 461 days — p=0.146